COMPARISON OF THREE ESCHERICHIA COLI STRAINS IN RECOMBINANT PRODUCTION OF HUMAN PAPILLOMAVIRUS 18 L1 PROTEIN

• Dr. Elsa Pimienta

• English

• escherichia coli
• human papillomavirus
• l1 major capsid protein
• vaccine candidate

Human papillomavirus (HPV) has been implicated in 99.7% of cervical squamous cell cancer cases (CCU) worldwide. HPV16 and HPV18 are known to cause around 70% of CCU. In particular, the genotype 18 (HPV-18) is the second most prevalent worldwide and it has been included in the commercial preventive vaccines against HPV; which are based on the antigenicity of the major capsid protein L1. These vaccines are highly expensive and are unavailable for the most needed populations in developing countries...